Wall Street brokerages expect Masimo Co. (NASDAQ:MASI) to post earnings of $0.75 per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Masimo’s earnings, with the highest EPS estimate coming in at $0.75 and the lowest estimate coming in at $0.73. Masimo also posted earnings per share of $0.75 in the same quarter last year. The company is expected to report its next earnings results on Wednesday, May 1st.

On average, analysts expect that Masimo will report full-year earnings of $3.08 per share for the current fiscal year. For the next year, analysts forecast that the business will post earnings of $3.52 per share, with EPS estimates ranging from $3.43 to $3.60. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Masimo.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, February 26th. The medical equipment provider reported $0.83 EPS for the quarter, topping the consensus estimate of $0.72 by $0.11. The firm had revenue of $223.10 million for the quarter, compared to analyst estimates of $220.96 million. Masimo had a return on equity of 19.53% and a net margin of 22.55%. Masimo’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.72 EPS.

Several equities analysts recently commented on MASI shares. Needham & Company LLC reissued a “buy” rating on shares of Masimo in a research report on Tuesday. BidaskClub lowered Masimo from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research raised Masimo from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $140.00 target price on shares of Masimo in a research report on Wednesday, February 27th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $132.00.

Masimo stock opened at $135.14 on Thursday. The company has a market cap of $7.14 billion, a P/E ratio of 44.60, a P/E/G ratio of 2.79 and a beta of 1.19. Masimo has a one year low of $84.46 and a one year high of $141.05.

In related news, Director Steven Barker sold 5,877 shares of the company’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $130.00, for a total transaction of $764,010.00. Following the completion of the transaction, the director now directly owns 70,709 shares in the company, valued at approximately $9,192,170. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Anand Sampath sold 30,000 shares of the company’s stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $115.00, for a total value of $3,450,000.00. Following the transaction, the chief operating officer now owns 42,518 shares of the company’s stock, valued at $4,889,570. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,722 shares of company stock worth $8,752,310. 12.60% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of MASI. FMR LLC increased its position in Masimo by 17.8% in the 4th quarter. FMR LLC now owns 3,889,562 shares of the medical equipment provider’s stock worth $417,622,000 after purchasing an additional 587,587 shares during the last quarter. Norges Bank purchased a new stake in Masimo in the 4th quarter valued at about $53,357,000. Fundsmith LLP purchased a new stake in Masimo in the 4th quarter valued at about $51,470,000. Marshall Wace LLP increased its stake in Masimo by 199.4% in the 3rd quarter. Marshall Wace LLP now owns 554,025 shares of the medical equipment provider’s stock valued at $68,998,000 after buying an additional 368,958 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new stake in Masimo in the 4th quarter valued at about $31,807,000. Hedge funds and other institutional investors own 83.80% of the company’s stock.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

See Also: Net Asset Value

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.